Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Prestige Consumer Healthcare Inc. (PBH) Market Cap & Valuation Ratios

Prestige Consumer Healthcare Inc. (PBH) has a market cap of $2.3B, a trailing P/E of 13.4 and a price-to-sales ratio of 2.0, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

PBHPrestige Consumer Healthcare Inc.Follow PBH — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
2.3B
P/E TTM
13.4
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Peers

drug manufacturers - specialty & generic · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
PBH2.313.43.813.010.4%-1%26%6%
AMLX3.0———-4.2%——-108%
SUPN2.4—2.6—0.8%+25%-16%-15%
PRGO2.2—1.2—5.4%-4%-38%-24%
TRLV2.0—1.7—9.3%-4%-24%-27%
BCRX2.0—2.1—19.1%+69%-33%—
XERS1.9—5.952.53.0%+36%11%28%
ANIP1.715.72.08.110.4%+31%15%13%
PAHC1.615.91.59.10.6%+17%13%14%
PCRX1.5104.12.114.912.4%+6%3%2%
ETON1.4—13.568.61.0%+81%15%42%
Median of these 1015.92.114.94.2%+25%3%2%

P/E 13.4 vs. a peer median of 15.9; EV/Sales 3.8 vs. 2.1. PBH's own P/E sits at the 12th percentile of its history.

Growth vs. price

each dot a company · hover or tap for values
1020501000%+10%+20%+30%revenue growth, TTM →P/E (log)PBHANIPPAHCPCRX

AMLX and SUPN and PRGO and TRLV and BCRX and XERS and ETON have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

Prestige Consumer Healthcare Inc. — questions

What is Prestige Consumer Healthcare Inc.'s market cap?
$2.3B.
What is Prestige Consumer Healthcare Inc.'s P/E ratio?
13.4 on trailing twelve-month earnings to 2026-06-30.
What is Prestige Consumer Healthcare Inc.'s price-to-sales ratio?
2.0.

Every figure on this page comes from Prestige Consumer Healthcare Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.